BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ros PR, Freeny PC, Harms SE, Seltzer SE, Davis PL, Chan TW, Stillman AE, Muroff LR, Runge VM, Nissenbaum MA. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology. 1995;196:481-488. [PMID: 7617864 DOI: 10.1148/radiology.196.2.7617864] [Cited by in Crossref: 211] [Cited by in F6Publishing: 182] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Quarta A, Piccirillo C, Mandriota G, Di Corato R. Nanoheterostructures (NHS) and Their Applications in Nanomedicine: Focusing on In Vivo Studies. Materials (Basel) 2019;12:E139. [PMID: 30609839 DOI: 10.3390/ma12010139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
2 Chan VO, Das JP, Gerstenmaier JF, Geoghegan J, Gibney RG, Collins CD, Skehan SJ, Malone DE. Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist®)-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre. Ir J Med Sci 2012;181:499-509. [DOI: 10.1007/s11845-012-0805-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
3 Saini S, Sharma R, Baron R, Turner D, Ros P, Hahn P, Small W, Delange E, Stillman A, Edelman R, Runge V, Outwater E. Multicentre Dose-Ranging Study on the Efficacy of USPIO Ferumoxtran-10 for Liver MR Imaging. Clinical Radiology 2000;55:690-5. [DOI: 10.1053/crad.2000.0504] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
4 Wolf GL, Halavaara JT. BASIC PRINCIPLES OF MR CONTRAST AGENTS. Magnetic Resonance Imaging Clinics of North America 1996;4:1-10. [DOI: 10.1016/s1064-9689(21)00550-x] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
5 Mergo PJ, Engelken JD, Helmberger T, Ros PR. MRI in focal liver disease: A comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents. J Magn Reson Imaging 1998;8:1073-8. [DOI: 10.1002/jmri.1880080511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 2011;3:3007. [DOI: 10.1039/c1nr10326a] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 18.4] [Reference Citation Analysis]
7 Nuzhina JV, Shtil AA, Prilepskii AY, Vinogradov VV. Preclinical Evaluation and Clinical Translation of Magnetite-Based Nanomedicines. Journal of Drug Delivery Science and Technology 2019;54:101282. [DOI: 10.1016/j.jddst.2019.101282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Gossuin Y, Gillis P, Hocq A, Vuong QL, Roch A. Magnetic resonance relaxation properties of superparamagnetic particles. WIREs Nanomed Nanobiotechnol 2009;1:299-310. [DOI: 10.1002/wnan.36] [Cited by in Crossref: 175] [Cited by in F6Publishing: 156] [Article Influence: 13.5] [Reference Citation Analysis]
9 Yoon SS, Tanabe KK. Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases. The Oncologist 1999;4:197-208. [DOI: 10.1634/theoncologist.4-3-197] [Cited by in Crossref: 88] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
10 Tanimoto A, Kadoya M, Kawamura Y, Kuwatsuru R, Gokan T, Hirohashi S. Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: Results of phase I and phase II clinical trials. J Magn Reson Imaging 2006;23:499-508. [DOI: 10.1002/jmri.20543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Mehta A, Ghaghada K, Mukundan S Jr. Molecular Imaging of Brain Tumors Using Liposomal Contrast Agents and Nanoparticles. Magn Reson Imaging Clin N Am 2016;24:751-63. [PMID: 27742115 DOI: 10.1016/j.mric.2016.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Gendelman HE, Anantharam V, Bronich T, Ghaisas S, Jin H, Kanthasamy AG, Liu X, McMillan J, Mosley RL, Narasimhan B, Mallapragada SK. Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine 2015;11:751-67. [PMID: 25645958 DOI: 10.1016/j.nano.2014.12.014] [Cited by in Crossref: 69] [Cited by in F6Publishing: 47] [Article Influence: 9.9] [Reference Citation Analysis]
13 de Schellenberger AA, Hauptmann R, Millward JM, Schellenberger E, Kobayashi Y, Taupitz M, Infante-Duarte C, Schnorr J, Wagner S. Synthesis of europium-doped VSOP, customized enhancer solution and improved microscopy fluorescence methodology for unambiguous histological detection. J Nanobiotechnology 2017;15:71. [PMID: 29017510 DOI: 10.1186/s12951-017-0301-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Kumar A, Chen F, Mozhi A, Zhang X, Zhao Y, Xue X, Hao Y, Zhang X, Wang PC, Liang XJ. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale 2013;5:8307-25. [PMID: 23860639 DOI: 10.1039/c3nr01525d] [Cited by in Crossref: 72] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
15 Morana G, Salviato E, Guarise A. Contrast agents for hepatic MRI. Cancer Imaging 2007;7 Spec No A:S24-7. [PMID: 17921081 DOI: 10.1102/1470-7330.2007.9001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
16 Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, Nesbit G, Stevens A, Jerosch-Herold M, Jacobs PM, Hoffman JM. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007;60:601-11; discussion 611-2. [PMID: 17415196 DOI: 10.1227/01.NEU.0000255350.71700.37] [Cited by in Crossref: 133] [Cited by in F6Publishing: 73] [Article Influence: 8.9] [Reference Citation Analysis]
17 Liu S, Jia B, Qiao R, Yang Z, Yu Z, Liu Z, Liu K, Shi J, Ouyang H, Wang F, Gao M. A novel type of dual-modality molecular probe for MR and nuclear imaging of tumor: preparation, characterization and in vivo application. Mol Pharm 2009;6:1074-82. [PMID: 19527074 DOI: 10.1021/mp900143a] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
18 Finn JP, Nguyen KL, Han F, Zhou Z, Salusky I, Ayad I, Hu P. Cardiovascular MRI with ferumoxytol. Clin Radiol 2016;71:796-806. [PMID: 27221526 DOI: 10.1016/j.crad.2016.03.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
19 Semelka RC, Lee JKT, Worawattanakul S, Noone TC, Patt RH, Ascher SM. Sequential use of ferumoxide particles and gadolinium chelate for the evaluation of focal liver lesions on MRI. J Magn Reson Imaging 1998;8:670-4. [DOI: 10.1002/jmri.1880080323] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
20 Wang YX. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg 2011;1:35-40. [PMID: 23256052 DOI: 10.3978/j.issn.2223-4292.2011.08.03] [Cited by in F6Publishing: 226] [Reference Citation Analysis]
21 Merkle EM, Haaga JR, Duerk JL, Jacobs GH, Brambs HJ, Lewin JS. MR imaging-guided radio-frequency thermal ablation in the pancreas in a porcine model with a modified clinical C-arm system. Radiology. 1999;213:461-467. [PMID: 10551227 DOI: 10.1148/radiology.213.2.r99nv21461] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
22 Kim YK, Kim CS, Lee YH, Kwak HS, Lee JM. Comparison of Superparamagnetic Iron Oxide–Enhanced and Gadobenate Dimeglumine–Enhanced Dynamic MRI for Detection of Small Hepatocellular Carcinomas. American Journal of Roentgenology 2004;182:1217-23. [DOI: 10.2214/ajr.182.5.1821217] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
23 Alger JR, Harreld JH, Chen S, Mintorovitch J, Lu DS. Time-to-echo optimization for spin echo magnetic resonance imaging of liver metastasis using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:586-94. [DOI: 10.1002/jmri.1223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
24 Merkle EM, Goldberg SN, Boll DT, Shankaranarayanan A, Boaz T, Jacobs GH, Wendt M, Lewin JS. Effects of Superparamagnetic Iron Oxide on Radiofrequency-induced Temperature Distribution: In Vitro Measurements in Polyacrylamide Phantoms and in Vivo Results in a Rabbit Liver Model. Radiology 1999;212:459-66. [DOI: 10.1148/radiology.212.2.r99au44459] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
25 Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057-1077. [PMID: 17530336 DOI: 10.1007/s11605-006-0061-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 136] [Article Influence: 10.1] [Reference Citation Analysis]
26 Clément O, Siauve N, Lewin M, de Kerviler E, Cuénod CA, Frija G. Contrast agents in magnetic resonance imaging of the liver: present and future. Biomed Pharmacother 1998;52:51-8. [PMID: 9755795 DOI: 10.1016/S0753-3322(98)80003-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
27 Zhang J, Ring HL, Hurley KR, Shao Q, Carlson CS, Idiyatullin D, Manuchehrabadi N, Hoopes PJ, Haynes CL, Bischof JC, Garwood M. Quantification and biodistribution of iron oxide nanoparticles in the primary clearance organs of mice using T1 contrast for heating. Magn Reson Med 2017;78:702-12. [PMID: 27667655 DOI: 10.1002/mrm.26394] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
28 Matsuo M, Kanematsu M, Itoh K, Murakami T, Maetani Y, Kondo H, Goshima S, Kako N, Hoshi H, Konishi J, Moriyama N, Nakamura H. Detection of malignant hepatic tumors with ferumoxides-enhanced MRI: comparison of five gradient-recalled echo sequences with different TEs. AJR Am J Roentgenol 2004;182:235-42. [PMID: 14684545 DOI: 10.2214/ajr.182.1.1820235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
29 Chang D, Kim B, Yun Y, Hur Y, Lee Y, Choi M, Yoon J, Seong J. SUPERPARAMAGNETIC IRON OXIDE-ENHANCED MAGNETIC RESONANCE IMAGING OF THE LIVER IN BEAGLE DOGS. Veterinary Radiology & Ultrasound 2002;43:37-42. [DOI: 10.1111/j.1740-8261.2002.tb00440.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
30 Schneider G, Reimer P, Mamann A, Kirchin MA, Morana G, Grazioli L. Contrast Agents in Abdominal Imaging: Current and Future Directions. Topics in Magnetic Resonance Imaging 2005;16:107-24. [DOI: 10.1097/01.rmr.0000189025.80743.5c] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
31 Cioni D, Lencioni R, Bartolozzi C. Percutaneous ablation of liver malignancies: imaging evaluation of treatment response. Eur J Ultrasound. 2001;13:73-93. [PMID: 11369521 DOI: 10.1016/s0929-8266(01)00122-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Mori K, Yoshioka H, Itai Y, Okamoto Y, Mori H, Takahashi N, Saida Y. Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. AJR Am J Roentgenol. 2000;175:1659-1664. [PMID: 11090400 DOI: 10.2214/ajr.175.6.1751659] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
33 Kim KW, Kim AY, Kim TK, Park SH, Kim HJ, Lee YK, Park M, Ha HK, Kim PN, Kim JC, Lee M. Small (≤ 2 cm) Hepatic Lesions in Colorectal Cancer Patients: Detection and Characterization on Mangafodipir Trisodium–Enhanced MRI. American Journal of Roentgenology 2004;182:1233-40. [DOI: 10.2214/ajr.182.5.1821233] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
34 Shahrouki P, Felker ER, Raman SS, Jeong WK, Lu DS, Finn JP. Steady-state ferumoxytol-enhanced MRI: early observations in benign abdominal organ masses and clinical implications. Abdom Radiol (NY) 2021. [PMID: 34689252 DOI: 10.1007/s00261-021-03271-w] [Reference Citation Analysis]
35 Kirchin MA, Pirovano G, Venetianer C, Spinazzi A. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 2001;14:281-94. [PMID: 11536405 DOI: 10.1002/jmri.1184] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
36 Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, Muldoon LL, Neuwelt EA. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010;30:15-35. [PMID: 19756021 DOI: 10.1038/jcbfm.2009.192] [Cited by in Crossref: 340] [Cited by in F6Publishing: 295] [Article Influence: 26.2] [Reference Citation Analysis]
37 Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60:314-323. [PMID: 17005349 DOI: 10.1016/j.ejrad.2006.06.021] [Cited by in Crossref: 165] [Cited by in F6Publishing: 138] [Article Influence: 10.3] [Reference Citation Analysis]
38 Siegelman ES, Outwater EK. Magnetic resonance imaging of focal and diffuse hepatic disease. Seminars in Ultrasound, CT and MRI 1998;19:2-34. [DOI: 10.1016/s0887-2171(98)90022-1] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
39 Hussain SM, Terkivatan T, Zondervan PE, Lanjouw E, de Rave S, Ijzermans JN, de Man RA. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics. 2004;24:3-17. [PMID: 14730031 DOI: 10.1148/rg.241035050] [Cited by in Crossref: 228] [Cited by in F6Publishing: 173] [Article Influence: 12.7] [Reference Citation Analysis]
40 Ward J, Naik KS, Guthrie JA, Wilson D, Robinson PJ. Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 1999;210:459-66. [PMID: 10207430 DOI: 10.1148/radiology.210.2.r99fe05459] [Cited by in Crossref: 187] [Cited by in F6Publishing: 158] [Article Influence: 8.1] [Reference Citation Analysis]
41 Kanematsu M, Itoh K, Matsuo M, Maetani Y, Ametani F, Kondo H, Kato H, Hoshi H. Malignant hepatic tumor detection with ferumoxides-enhanced MR imaging with a 1.5-T system: Comparison of four imaging pulse sequences. J Magn Reson Imaging 2001;13:249-57. [DOI: 10.1002/1522-2586(200102)13:2<249::aid-jmri1036>3.0.co;2-c] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
42 Higashihara H, Murakami T, Kim T, Hori M, Onishi H, Nakata S, Osuga K, Tomoda K, Nakamura H. Differential diagnosis between metastatic tumors and nonsolid benign lesions of the liver using ferucarbotran-enhanced MR imaging. European Journal of Radiology 2010;73:125-30. [DOI: 10.1016/j.ejrad.2008.09.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
43 Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41:2971-3010. [PMID: 22388185 DOI: 10.1039/c2cs15344k] [Cited by in Crossref: 1141] [Cited by in F6Publishing: 1006] [Article Influence: 114.1] [Reference Citation Analysis]
44 Merkle EM, Boll DT, Boaz T, Duerk JL, Chung YC, Jacobs GH, Varnes ME, Lewin JS. MRI-guided radiofrequency thermal ablation of implanted VX2 liver tumors in a rabbit model: Demonstration of feasibility at 0.2 T. Magn Reson Med 1999;42:141-9. [DOI: 10.1002/(sici)1522-2594(199907)42:1<141::aid-mrm19>3.0.co;2-i] [Cited by in Crossref: 46] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
45 Henninger B, Petersen J, Jaschke W. [Radiological diagnosis of primary hepatic malignancy]. Wien Med Wochenschr 2013;163:113-22. [PMID: 23392810 DOI: 10.1007/s10354-013-0179-3] [Reference Citation Analysis]
46 Ward J, Guthrie JA, Wilson D, Arnold P, Lodge JP, Toogood GJ, Wyatt JI, Robinson PJ. Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging--comparison of optimized sequences. Radiology. 2003;228:709-718. [PMID: 12888620 DOI: 10.1148/radiol.2283020376] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
47 Daldrup-Link HE. Ten Things You Might Not Know about Iron Oxide Nanoparticles. Radiology. 2017;284:616-629. [PMID: 28825888 DOI: 10.1148/radiol.2017162759] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 14.4] [Reference Citation Analysis]
48 Zheng WW, Zhou KR, Chen ZW, Shen JZ, Chen CZ, Zhang SJ. Characterization of focal hepatic lesions with SPIO-enhanced MRI. World J Gastroenterol 2002; 8(1): 82-86 [PMID: 11833077 DOI: 10.3748/wjg.v8.i1.82] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
49 Lim JH, Choi D, Cho SK, Kim SH, Lee WJ, Lim HK, Park CK, Paik SW, Kim YI. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology. 2001;220:669-676. [PMID: 11526265 DOI: 10.1148/radiol.2203001777] [Cited by in Crossref: 86] [Cited by in F6Publishing: 67] [Article Influence: 4.1] [Reference Citation Analysis]
50 Kehagias DT, Gouliamos AD, Smyrniotis V, Vlahos LJ. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A). J Magn Reson Imaging 2001;14:595-601. [DOI: 10.1002/jmri.1224] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
51 Winer JL, Liu CY, Apuzzo ML. The Use of Nanoparticles as Contrast Media in Neuroimaging: A Statement on Toxicity. World Neurosurgery 2012;78:709-11. [DOI: 10.1016/j.wneu.2011.08.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
52 Raman SS, Leary C, Bluemke DA, Amendola M, Sahani D, McTavish JD, Brody J, Outwater E, Mitchell D, Sheafor DH. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr. 2010;34:163-172. [PMID: 20351497 DOI: 10.1097/rct.0b013e3181c89d87] [Cited by in Crossref: 50] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
53 Low RN. Contrast agents for MR imaging of the liver. J Magn Reson Imaging 1997;7:56-67. [DOI: 10.1002/jmri.1880070109] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
54 Pauleit D, Textor J, Bachmann R, Conrad R, Flacke S, Layer G, Kreft B, Schild H. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology. 2002;222:73-80. [PMID: 11756708 DOI: 10.1148/radiol.2221001599] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
55 Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features. RadioGraphics 2008;28:747-69. [DOI: 10.1148/rg.283055108] [Cited by in Crossref: 130] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis]
56 Taylor HM, Ros PR. HEPATIC IMAGING. Radiologic Clinics of North America 1998;36:237-45. [DOI: 10.1016/s0033-8389(05)70019-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
57 Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000;12:205-13. [DOI: 10.1002/1522-2586(200008)12:2<205::aid-jmri1>3.0.co;2-p] [Cited by in Crossref: 167] [Cited by in F6Publishing: 23] [Article Influence: 7.6] [Reference Citation Analysis]
58 del Frate C, Bazzocchi M, Mortele KJ, Zuiani C, Londero V, Como G, Zanardi R, Ros PR. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology. 2002;225:766-772. [PMID: 12461259 DOI: 10.1148/radiol.2253011854] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
59 Kim MJ, Kim JH, Lim JS, Oh YT, Chung JJ, Choi JS, Lee WJ, Kim KW. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004;20:612-21. [PMID: 15390224 DOI: 10.1002/jmri.20174] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
60 Tourdias T, Dousset V. Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy. Neurotherapeutics 2013;10:111-23. [PMID: 23132327 DOI: 10.1007/s13311-012-0155-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
61 Ros PR, Mortele KJ. Hepatic imaging: An Overview. Clinics in Liver Disease 2002;6:1-16. [DOI: 10.1016/s1089-3261(03)00063-1] [Cited by in Crossref: 17] [Article Influence: 0.9] [Reference Citation Analysis]
62 Bluemke DA, Weber TM, Rubin D, de Lange EE, Semelka R, Redvanly RD, Chezmar J, Outwater E, Carlos R, Saini S, Holland GA, Mammone JF, Brown JJ, Milestone B, Javitt MC, Jacobs P. Hepatic MR Imaging with Ferumoxides: Multicenter Study of Safety and Effectiveness of Direct Injection Protocol. Radiology 2003;228:457-64. [DOI: 10.1148/radiol.2282012061] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
63 Thomsen HS, Morcos SK. ESUR guidelines on contrast media. Abdom Imaging 2006;31:131-40. [DOI: 10.1007/s00261-005-0380-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
64 Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, Saini S, Maravilla KR, Feldman DE, Schmiedl UP, Brunberg JA, Francis IR, Harms SE, Som PM, Tempany CM. Evaluation of Neck and Body Metastases to Nodes with Ferumoxtran 10–enhanced MR Imaging: Phase III Safety and Efficacy Study. Radiology 2003;228:777-88. [DOI: 10.1148/radiol.2283020872] [Cited by in Crossref: 216] [Cited by in F6Publishing: 178] [Article Influence: 11.4] [Reference Citation Analysis]
65 Liu D, Cito S, Zhang Y, Wang C, Sikanen TM, Santos HA. A Versatile and Robust Microfluidic Platform Toward High Throughput Synthesis of Homogeneous Nanoparticles with Tunable Properties. Adv Mater 2015;27:2298-304. [DOI: 10.1002/adma.201405408] [Cited by in Crossref: 133] [Cited by in F6Publishing: 116] [Article Influence: 19.0] [Reference Citation Analysis]
66 Lee JM, Kim IH, Kwak HS, Youk JH, Han YM, Kim CS. Detection of small hypervascular hepatocellular carcinomas in cirrhotic patients: comparison of superparamagnetic iron oxide-enhanced MR imaging with dual-phase spiral CT. Korean J Radiol 2003;4:1-8. [PMID: 12679628 DOI: 10.3348/kjr.2003.4.1.1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
67 Tschulik K, Haddou B, Omanović D, Rees NV, Compton RG. Coulometric sizing of nanoparticles: Cathodic and anodic impact experiments open two independent routes to electrochemical sizing of Fe3O4 nanoparticles. Nano Res 2013;6:836-41. [DOI: 10.1007/s12274-013-0361-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
68 Huang RY, Liu ZH, Weng WH, Chang CW. Magnetic nanocomplexes for gene delivery applications. J Mater Chem B 2021;9:4267-86. [PMID: 33942822 DOI: 10.1039/d0tb02713h] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Idee J, Port M, Raynal I, Schaefer M, Bonnemain B, Prigent P, Robert P, Robic C, Corot C. Superparamagnetic Nanoparticles of Iron Oxides for Magnetic Resonance Imaging Applications. In: Kumar CSSR, editor. Nanotechnologies for the Life Sciences. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2007. [DOI: 10.1002/9783527610419.ntls0108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
70 Reimer P, Müller M, Marx C, Balzer T. Evaluation of the Time Window for Resovist-Enhanced T2-Weighted MRI of the Liver. Academic Radiology 2002;9:S336-8. [DOI: 10.1016/s1076-6332(03)80222-2] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
71 Morcos SK, Bellin M, Thomsen HS, Almén T, Aspelin P, Heinz-peer G, Jakobsen JÅ, Liss P, Oyen R, Stacul F, van der Molen AJ, Webb JA. Reducing the risk of iodine-based and MRI contrast media administration: Recommendation for a questionnaire at the time of booking. European Journal of Radiology 2008;66:225-9. [DOI: 10.1016/j.ejrad.2008.01.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
72 Bartolozzi C, Cioni D, Donati F, Granai G, Lencioni R. Imaging Evaluation of Tumor Response. In: Bartolozzi C, Lencioni R, editors. Liver Malignancies. Berlin: Springer Berlin Heidelberg; 1999. pp. 467-87. [DOI: 10.1007/978-3-642-58641-5_30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
73 Goshima S, Kanematsu M, Matsuo M, Murakami T, Hori M, Takamura M, Kondo H, Kako N, Moriyama N, Nakamura H, Hoshi H. Detection of malignant hepatic tumors with ferumoxide-enhanced MR imaging: usefulness of multishot and single-shot fast spin echo sequences. Magnetic Resonance Imaging 2004;22:379-88. [DOI: 10.1016/j.mri.2004.01.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
74 Oswald P, Clement O, Chambon C, Schouman-claeys E, Frija G. Liver positive enhancement after injection of superparamagnetic nanoparticles: Respective role of circulating and uptaken particles. Magnetic Resonance Imaging 1997;15:1025-31. [DOI: 10.1016/s0730-725x(97)00004-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
75 Winston CB, Schwartz LH. Advances in Magnetic Resonance Imaging: Applications in Body Imaging. Cancer Investigation 2009;16:413-20. [DOI: 10.3109/07357909809115782] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
76 Halavaara JT, Lamminen AE. Technical Note. MnDPDP as a Negative Hepatic Contrast Agent: Evaluation of STIR Imaging Compared with T1-Weighted SE and GE Techniques: . Journal of Computer Assisted Tomography 1997;21:94-9. [DOI: 10.1097/00004728-199701000-00017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
77 Wang K, Li L, Xu X, Lu L, Wang J, Wang S, Wang Y, Jin Z, Zhang JZ, Jiang Y. Fe 3 O 4 @ Astragalus Polysaccharide Core–Shell Nanoparticles for Iron Deficiency Anemia Therapy and Magnetic Resonance Imaging in Vivo. ACS Appl Mater Interfaces 2019;11:10452-61. [DOI: 10.1021/acsami.8b18648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
78 Lencioni R, Cioni D, Crocetti L, Pina CD, Bartolozzi C. Magnetic resonance imaging of liver tumors. Journal of Hepatology 2004;40:162-71. [DOI: 10.1016/s0168-8278(03)00455-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
79 Ling D, Hyeon T. Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small 2013;9:1450-66. [PMID: 23233377 DOI: 10.1002/smll.201202111] [Cited by in Crossref: 293] [Cited by in F6Publishing: 245] [Article Influence: 29.3] [Reference Citation Analysis]
80 Knobloch G, Colgan T, Wiens CN, Wang X, Schubert T, Hernando D, Sharma SD, Reeder SB. Relaxivity of Ferumoxytol at 1.5 T and 3.0 T. Invest Radiol 2018;53:257-63. [PMID: 29215401 DOI: 10.1097/RLI.0000000000000434] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
81 Chanyaputhipong J, Low SC, Chow PK. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol. 2011;2011:489342. [PMID: 21994860 DOI: 10.4061/2011/489342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
82 Haimerl M, Wächtler M, Platzek I, Müller-Wille R, Niessen C, Hoffstetter P, Schreyer AG, Stroszczynski C, Wiggermann P. Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions. BMC Med Imaging 2013;13:41. [PMID: 24289722 DOI: 10.1186/1471-2342-13-41] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
83 Ros PR, Davis GL. The incidental focal liver lesion: Photon, proton, or needle? Hepatology 1998;27:1183-90. [DOI: 10.1002/hep.510270501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
84 Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J Drug Target 1998;6:167-74. [PMID: 9888302 DOI: 10.3109/10611869808997890] [Cited by in Crossref: 269] [Cited by in F6Publishing: 224] [Article Influence: 11.7] [Reference Citation Analysis]
85 Joo J. Diagnostic and Therapeutic Nanomedicine. Adv Exp Med Biol 2021;1310:401-47. [PMID: 33834444 DOI: 10.1007/978-981-33-6064-8_15] [Reference Citation Analysis]
86 Frate CD, Zuiani C, Londero V, Como G, Bazzocchi M, Mortele K, Ros PR. Comparing Levovist-Enhanced Pulse Inversion Harmonic Imaging and Ferumoxides-Enhanced MR Imaging of Hepatic Metastases. American Journal of Roentgenology 2003;180:1339-46. [DOI: 10.2214/ajr.180.5.1801339] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
87 Wu Y, Wang H, Fan C, Xu Z, Liu B, Liu W. A smart indwelling needle with on-demand switchable anticoagulant and hemostatic activities. Mater Horiz 2020;7:1091-100. [DOI: 10.1039/c9mh01619h] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Häfeli UO, Aue J, Damani J. The biocompatibility and toxicity of magnetic particles. Magnetic Cell Separation. Elsevier; 2007. pp. 163-223. [DOI: 10.1016/s0075-7535(06)32007-4] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
89 Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology. 2001;218:27-38. [PMID: 11152776 DOI: 10.1148/radiology.218.1.r01ja2427] [Cited by in Crossref: 239] [Cited by in F6Publishing: 197] [Article Influence: 11.4] [Reference Citation Analysis]
90 Ward J, Chen F, Guthrie JA, Wilson D, Lodge JP, Wyatt JI, Robinson PJ. Hepatic lesion detection after superparamagnetic iron oxide enhancement: comparison of five T2-weighted sequences at 1.0 T by using alternative-free response receiver operating characteristic analysis. Radiology. 2000;214:159-166. [PMID: 10644117 DOI: 10.1148/radiology.214.1.r00ja21159] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 2.6] [Reference Citation Analysis]
91 Oudkerk M, Torres CG, Song B, König M, Grimm J, Fernandez-cuadrado J, Op de Beeck B, Marquardt M, van Dijk P, de Groot JC. Characterization of Liver Lesions with Mangafodipir Trisodium–enhanced MR Imaging: Multicenter Study Comparing MR and Dual-Phase Spiral CT. Radiology 2002;223:517-24. [DOI: 10.1148/radiol.2232010318] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 4.0] [Reference Citation Analysis]
92 van Etten B, van der Sijp J, Kruyt R, Oudkerk M, van der Holt B, Wiggers T. Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases. Eur J Surg Oncol 2002;28:645-51. [PMID: 12359202 DOI: 10.1053/ejso.2001.1251] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
93 Goshima S, Kanematsu M, Matsuo M, Kondo H, Kako N, Yokoyama R, Hoshi H, Moriyama N. Malignant hepatic tumor detection with ferumoxide-enhanced magnetic resonance imaging: Is chemical-shift-selective fat suppression necessary for fast spin-echo sequence? J Magn Reson Imaging 2004;20:75-82. [DOI: 10.1002/jmri.20091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
94 Mclachlan SJ, Morris M, Lucas MA, Baum LM. Preliminary clinical experience with AMI 227. Academic Radiology 1996;3:S295-6. [DOI: 10.1016/s1076-6332(96)80561-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, Fusté LC, Heinz-Peer G, Judmaier W, Laniado M. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467. [PMID: 18058107 DOI: 10.1007/s00330-007-0716-9] [Cited by in Crossref: 301] [Cited by in F6Publishing: 271] [Article Influence: 20.1] [Reference Citation Analysis]
96 Mann GN, Marx HF, Lai LL, Wagman LD. Clinical and Cost Effectiveness of a New Hepatocellular MRI Contrast Agent, Mangafodipir Trisodium, in the Preoperative Assessment of Liver Resectability. Ann Surg Oncol 2001;8:573-9. [DOI: 10.1007/s10434-001-0573-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
97 Gu L, Fang RH, Sailor MJ, Park JH. In vivo clearance and toxicity of monodisperse iron oxide nanocrystals. ACS Nano 2012;6:4947-54. [PMID: 22646927 DOI: 10.1021/nn300456z] [Cited by in Crossref: 142] [Cited by in F6Publishing: 130] [Article Influence: 14.2] [Reference Citation Analysis]
98 Knollmann FD, Böck JC, Teltenkötter S, Wlodarczyk W, Mühler A, Vogl TJ, Felix R. Evaluation of portal MR angiography using superparamagnetic iron oxide. J Magn Reson Imaging 1997;7:191-6. [DOI: 10.1002/jmri.1880070129] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
99 Wu YJ, Muldoon LL, Varallyay C, Markwardt S, Jones RE, Neuwelt EA. In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging. American Journal of Physiology-Cell Physiology 2007;293:C1698-708. [DOI: 10.1152/ajpcell.00215.2007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
100 Bartolozzi C, Battaglia V, Bozzi E. Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 2011;36:290-9. [DOI: 10.1007/s00261-011-9687-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
101 Marin D, Brancatelli G, Federle MP, Lagalla R, Catalano C, Passariello R, Midiri M, Vilgrain V. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media. Clin Radiol. 2008;63:577-585. [PMID: 18374723 DOI: 10.1016/j.crad.2007.06.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
102 Anzai Y, Prince MR. Iron oxide-enhanced MR lymphography: The evaluation of cervical lymph node metastases in head and neck cancer. J Magn Reson Imaging 1997;7:75-81. [DOI: 10.1002/jmri.1880070111] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
103 Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem Rev 2012;112:2323-38. [PMID: 22216932 DOI: 10.1021/cr2002596] [Cited by in Crossref: 382] [Cited by in F6Publishing: 322] [Article Influence: 34.7] [Reference Citation Analysis]
104 Kim YK, Kim CS, Kwak HS, Lee JM. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging. J Magn Reson Imaging. 2004;20:826-837. [PMID: 15503325 DOI: 10.1002/jmri.20188] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
105 Vuong QL, Gillis P, Roch A, Gossuin Y. Magnetic resonance relaxation induced by superparamagnetic particles used as contrast agents in magnetic resonance imaging: a theoretical review. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017;9. [PMID: 28398013 DOI: 10.1002/wnan.1468] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
106 Anzai Y. Superparamagnetic Iron Oxide Nanoparticles: Nodal Metastases and Beyond. Topics in Magnetic Resonance Imaging 2004;15:103-11. [DOI: 10.1097/01.rmr.0000130602.65243.87] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
107 Cheng WZ, Zeng MS, Yan FH, Rao SX, Shen JZ, Chen CZ, Zhang SJ, Shi WB. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 2007; 13(36): 4891-4896 [PMID: 17828821 DOI: 10.3748/wjg.v13.i36.4891] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
108 Ros PR, Mortele KJ. Diffuse liver disease. Clinics in Liver Disease 2002;6:181-201. [DOI: 10.1016/s1089-3261(03)00072-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
109 Schultz JF, Bell JD, Goldstein RM, Kuhn JA, McCarty TM. Hepatic tumor imaging using iron oxide MRI: comparison with computed tomography, clinical impact, and cost analysis. Ann Surg Oncol 1999;6:691-8. [PMID: 10560856 DOI: 10.1007/pl00021736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 0.3] [Reference Citation Analysis]
110 Wang AZ, Gu FX, Farokhzad OC. Nanoparticles for Cancer Diagnosis and Therapy. In: Webster TJ, editor. Safety of Nanoparticles. New York: Springer; 2009. pp. 209-35. [DOI: 10.1007/978-0-387-78608-7_10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
111 Arbab AS, Ichikawa T, Sou H, Araki T, Nakajima H, Ishigame K, Yoshikawa T, Kumagai H. Ferumoxides-enhanced Double-Echo T2-weighted MR Imaging in Differentiating Metastases from Nonsolid Benign Lesions of the Liver. Radiology 2002;225:151-8. [DOI: 10.1148/radiol.2251011090] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
112 Rotenberg MY, Gabay H, Etzion Y, Cohen S. Feasibility of Leadless Cardiac Pacing Using Injectable Magnetic Microparticles. Sci Rep 2016;6:24635. [PMID: 27091192 DOI: 10.1038/srep24635] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
113 Seltzer SE, Getty DJ, Pickett RM, Swets JA, Sica G, Brown J, Saini S, Mattrey RF, Harmon B, Francis IR, Chezmar J, Schnall MO, Siegelman ES, Ballerini R, Bhat S. Multimodality diagnosis of liver tumors: feature analysis with CT, liver-specific and contrast-enhanced MR, and a computer model. Acad Radiol 2002;9:256-69. [PMID: 11887942 DOI: 10.1016/s1076-6332(03)80368-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
114 Paley MR, Mergo PJ, Torres GM, Ros PR. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol. 2000;175:159-163. [PMID: 10882267 DOI: 10.2214/ajr.175.1.1750159] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 2.9] [Reference Citation Analysis]
115 Frantellizzi V, Conte M, Pontico M, Pani A, Pani R, De Vincentis G. New Frontiers in Molecular Imaging with Superparamagnetic Iron Oxide Nanoparticles (SPIONs): Efficacy, Toxicity, and Future Applications. Nucl Med Mol Imaging 2020;54:65-80. [PMID: 32377258 DOI: 10.1007/s13139-020-00635-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
116 Gao Y, Shi X, Shen M. Intelligent Design of Ultrasmall Iron Oxide Nanoparticle-Based Theranostics. ACS Appl Mater Interfaces 2021;13:45119-29. [PMID: 34530608 DOI: 10.1021/acsami.1c13341] [Reference Citation Analysis]
117 Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, Casalino DD, Davis PL, Francis IR, Krinsky G. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005;237:89-98. [PMID: 16126918 DOI: 10.1148/radiol.2371031842] [Cited by in Crossref: 188] [Cited by in F6Publishing: 163] [Article Influence: 11.1] [Reference Citation Analysis]
118 Ishiyama K, Hashimoto M, Izumi J, Watarai J, Shibata S, Sato T, Yamamoto Y. Tumor-liver contrast and subjective tumor conspicuity of respiratory-triggered T2-weighted fast spin-echo sequence compared with T2*-weighted gradient recalled-echo sequence for ferucarbotran-enhanced magnetic resonance imaging of hepatic malignant tumors. J Magn Reson Imaging 2008;27:1322-6. [PMID: 18504744 DOI: 10.1002/jmri.21399] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
119 Imam K, Bluemke DA. MR IMAGING IN THE EVALUATION OF HEPATIC METASTASES. Magnetic Resonance Imaging Clinics of North America 2000;8:741-56. [DOI: 10.1016/s1064-9689(21)00641-3] [Cited by in Crossref: 15] [Article Influence: 0.7] [Reference Citation Analysis]
120 Reimer P, Jähnke N, Fiebich M, Schima W, Deckers F, Marx C, Holzknecht N, Saini S. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology. 2000;217:152-158. [PMID: 11012438 DOI: 10.1148/radiology.217.1.r00oc31152] [Cited by in Crossref: 141] [Cited by in F6Publishing: 122] [Article Influence: 6.4] [Reference Citation Analysis]
121 Braga L, Semelka RC. Magnetic Resonance Imaging Features of Focal Liver Lesions after Intervention. Topics in Magnetic Resonance Imaging 2005;16:99-106. [DOI: 10.1097/01.rmr.0000189026.57872.8c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
122 Paley MR, Ros PR. Hepatic metastases. Radiol Clin North Am. 1998;36:349-363. [PMID: 9520987 DOI: 10.1016/s0033-8389(05)70027-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
123 Morana G, Grazioli L, Testoni M, Caccia P, Procacci C. Contrast Agents for Hepatic Magnetic Resonance Imaging: . Topics in Magnetic Resonance Imaging 2002;13:117-50. [DOI: 10.1097/00002142-200206000-00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
124 Ring HL, Zhang J, Klein ND, Eberly LE, Haynes CL, Garwood M. Establishing the overlap of IONP quantification with echo and echoless MR relaxation mapping. Magn Reson Med 2018;79:1420-8. [PMID: 28653344 DOI: 10.1002/mrm.26800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
125 Helmberger T, Semelka RC. NEW CONTRAST AGENTS FOR IMAGING THE LIVER. Magnetic Resonance Imaging Clinics of North America 2001;9:745-66. [DOI: 10.1016/s1064-9689(21)00272-5] [Cited by in Crossref: 17] [Article Influence: 0.8] [Reference Citation Analysis]
126 Ji H, Ros PR. Magnetic resonance imaging. Liver-specific contrast agents. Clin Liver Dis 2002;6:73-90. [PMID: 11933597 DOI: 10.1016/s1089-3261(03)00067-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
127 Ward J, Robinson PJ. COMBINED USE OF MR CONTRAST AGENTS FOR EVALUATING LIVER DISEASE. Magnetic Resonance Imaging Clinics of North America 2001;9:767-83. [DOI: 10.1016/s1064-9689(21)00273-7] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
128 Lencioni R, Pina CD, Bruix J, Majno P, Grazioli L, Morana G, Filippone A, Laghi A, Bartolozzi C. Clinical Management of Hepatic Malignancies: Ferucarbotran-Enhanced Magnetic Resonance Imaging Versus Contrast-Enhanced Spiral Computed Tomography. Dig Dis Sci 2005;50:533-7. [DOI: 10.1007/s10620-005-2469-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
129 Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001;5:123-44. [PMID: 11218911 DOI: 10.1016/s1089-3261(05)70157-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
130 Kamel IR, Bluemke DA. MR imaging of liver tumors. Radiologic Clinics of North America 2003;41:51-65. [DOI: 10.1016/s0033-8389(02)00067-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
131 Kumano S, Murakami T, Kim T, Hori M, Okada A, Sugiura T, Noguchi Y, Kawata S, Tomoda K, Nakamura H. Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions. AJR Am J Roentgenol 2003;181:1335-9. [PMID: 14573430 DOI: 10.2214/ajr.181.5.1811335] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
132 Schultz JF, Bell JD, Goldstein RM, Kuhn JA, Mccarty TM. Hepatic Tumor Imaging Using Iron Oxide MRI: Comparison With Computed Tomography, Clinical Impact, and Cost Analysis. Ann Surg Oncol 1999;6:691-8. [DOI: 10.1007/s10434-999-0691-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
133 Häfeli UO, Pauer GJ. In vitro and in vivo toxicity of magnetic microspheres. Journal of Magnetism and Magnetic Materials 1999;194:76-82. [DOI: 10.1016/s0304-8853(98)00560-5] [Cited by in Crossref: 110] [Article Influence: 4.8] [Reference Citation Analysis]
134 Berman AJ, Zahalsky MP, Okon SA, Wagner JR. Distinguishing splenosis from renal masses using ferumoxide-enhanced magnetic resonance imaging. Urology 2003;62:748. [DOI: 10.1016/s0090-4295(03)00509-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
135 Woltz S, Hiergeist R, Görnert P, Rüssel C. Magnetite nanoparticles prepared by the glass crystallization method and their physical properties. Journal of Magnetism and Magnetic Materials 2006;298:7-13. [DOI: 10.1016/j.jmmm.2005.02.067] [Cited by in Crossref: 57] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
136 Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005;15:220-8. [DOI: 10.1007/s00330-004-2570-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 3.8] [Reference Citation Analysis]
137 Earls JP, Bluemke DA. NEW MR IMAGING CONTRAST AGENTS. Magnetic Resonance Imaging Clinics of North America 1999;7:255-73. [DOI: 10.1016/s1064-9689(21)00021-0] [Cited by in Crossref: 20] [Article Influence: 0.9] [Reference Citation Analysis]
138 Reimer P, Allkemper T, Matuszewski L, Balzer T. Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555 A). J Magn Reson Imaging 1999;10:65-71. [DOI: 10.1002/(sici)1522-2586(199907)10:1<65::aid-jmri9>3.0.co;2-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Ugga L, Romeo V, Tedeschi E, Brunetti A, Quarantelli M. Superparamagnetic iron oxide nanocolloids in MRI studies of neuroinflammation. J Neurosci Methods 2018;310:12-23. [PMID: 29913184 DOI: 10.1016/j.jneumeth.2018.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
140 Niemirowicz K, Markiewicz KH, Wilczewska AZ, Car H. Magnetic nanoparticles as new diagnostic tools in medicine. Adv Med Sci 2012;57:196-207. [PMID: 23154427 DOI: 10.2478/v10039-012-0031-9] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
141 Savranoglu P, Obuz F, Karasu S, Coker A, Secil M, Sagol O, Igci E, Dicle O, Astarcioglu I. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging 2006;30:377-81. [PMID: 17101405 DOI: 10.1016/j.clinimag.2006.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
142 Scott J, Ward J, Guthrie J, Wilson D, Robinson P. MRI of liver: a comparison of CNR enhancement using high dose and low dose ferumoxide infusion in patients with colorectal liver metastases. Magnetic Resonance Imaging 2000;18:297-303. [DOI: 10.1016/s0730-725x(00)00116-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
143 Ba-ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 2009;19:342-57. [DOI: 10.1007/s00330-008-1172-x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 113] [Article Influence: 9.0] [Reference Citation Analysis]
144 Bluemke DA, Paulson EK, Choti MA, DeSena S, Clavien PA. Detection of hepatic lesions in candidates for surgery: comparison of ferumoxides-enhanced MR imaging and dual-phase helical CT. AJR Am J Roentgenol. 2000;175:1653-1658. [PMID: 11090399 DOI: 10.2214/ajr.175.6.1751653] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
145 Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, Kamura T, Gabata T, Murakami T, Ito K. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141. [PMID: 20098330 DOI: 10.1097/rli.0b013e3181caea5b] [Cited by in Crossref: 164] [Cited by in F6Publishing: 53] [Article Influence: 13.7] [Reference Citation Analysis]
146 Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 2007;17:2519-30. [DOI: 10.1007/s00330-007-0602-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
147 Choi D, Kim SH, Lim JH, Lee WJ, Jang H, Lee SJ, Lim HK. Preoperative Detection of Hepatocellular Carcinoma: Ferumoxides-Enhanced MR Imaging Versus Combined Helical CT During Arterial Portography and CT Hepatic Arteriography. American Journal of Roentgenology 2001;176:475-82. [DOI: 10.2214/ajr.176.2.1760475] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
148 Robinson P. The characterization of liver tumours by MRI. Clinical Radiology 1996;51:749-61. [DOI: 10.1016/s0009-9260(96)80002-x] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
149 Woltz S, Rüssel C. Self organized nano crystallinity of magnetite precipitated from a 4.9Na2O·33.3CaO·17.1Fe2O3·44.7B2O3 glass. Journal of Non-Crystalline Solids 2004;337:226-31. [DOI: 10.1016/j.jnoncrysol.2004.04.015] [Cited by in Crossref: 39] [Article Influence: 2.2] [Reference Citation Analysis]
150 Petersein J, Saini S, Weissleder R. LIVER II: IRON OXIDE-BASED RETICULOENDOTHELIAL CONTRAST AGENTS FOR MR IMAGING. Magnetic Resonance Imaging Clinics of North America 1996;4:53-60. [DOI: 10.1016/s1064-9689(21)00553-5] [Cited by in Crossref: 18] [Article Influence: 0.7] [Reference Citation Analysis]
151 Limanond P, Raman SS, Sayre J, Lu DS. Comparison of dynamic gadolinium-enhanced and ferumoxides-enhanced MRI of the liver on high- and low-field scanners. J Magn Reson Imaging 2004;20:640-7. [DOI: 10.1002/jmri.20165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
152 Mori H, Yoshioka H, Ahmadi T, Saida Y, Ohara K, Itai Y. Early Radiation Effects on the Liver Demonstrated on Superparamagnetic Iron Oxide-Enhanced T1-Weighted MRI: . Journal of Computer Assisted Tomography 2000;24:648-51. [DOI: 10.1097/00004728-200007000-00025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
153 Choi JS, Kim MJ, Kim JH, Choi JY, Chung YE, Park MS, Kim KW. Comparison of multi-echo and single-echo gradient-recalled echo sequences for SPIO-enhanced liver MRI at 3 T. Clin Radiol 2010;65:916-23. [PMID: 20933647 DOI: 10.1016/j.crad.2010.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
154 Kubaska S, Sahani DV, Saini S, Hahn PF, Halpern E. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization. Clin Radiol 2001;56:410-5. [PMID: 11384141 DOI: 10.1053/crad.2000.0673] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
155 Onishi H, Murakami T, Kim T, Hori M, Iannaccone R, Kuwabara M, Abe H, Nakata S, Osuga K, Tomoda K, Passariello R, Nakamura H. Hepatic metastases: detection with multi-detector row CT, SPIO-enhanced MR imaging, and both techniques combined. Radiology 2006;239:131-8. [PMID: 16484347 DOI: 10.1148/radiol.2383041825] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
156 Aswendt M, Henn N, Michalk S, Schneider G, Steiner MS, Bissa U, Dose C, Hoehn M. Novel bimodal iron oxide particles for efficient tracking of human neural stem cells in vivo. Nanomedicine (Lond) 2015;10:2499-512. [PMID: 26296195 DOI: 10.2217/NNM.15.94] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
157 Lunov O, Syrovets T, Röcker C, Tron K, Nienhaus GU, Rasche V, Mailänder V, Landfester K, Simmet T. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 2010;31:9015-22. [PMID: 20739059 DOI: 10.1016/j.biomaterials.2010.08.003] [Cited by in Crossref: 134] [Cited by in F6Publishing: 123] [Article Influence: 11.2] [Reference Citation Analysis]
158 Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT. Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology. 2003;228:719-726. [PMID: 12881583 DOI: 10.1148/radiol.2283020735] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 3.1] [Reference Citation Analysis]
159 Bellin M, Webb JAW, Van Der Molen AJ, Thomsen HS, Morcos SK; Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Safety of MR liver specific contrast media. Eur Radiol 2005;15:1607-14. [DOI: 10.1007/s00330-004-2612-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
160 Gheidari D, Mehrdad M, Maleki S, Hosseini S. Synthesis and potent antimicrobial activity of CoFe2O4 nanoparticles under visible light. Heliyon 2020;6:e05058. [PMID: 33083590 DOI: 10.1016/j.heliyon.2020.e05058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am. 1998;36:287-297. [PMID: 9520982 DOI: 10.1016/s0033-8389(05)70022-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
162 Uchida M, Terashima M, Cunningham CH, Suzuki Y, Willits DA, Willis AF, Yang PC, Tsao PS, Mcconnell MV, Young MJ, Douglas T. A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn Reson Med 2008;60:1073-81. [DOI: 10.1002/mrm.21761] [Cited by in Crossref: 110] [Cited by in F6Publishing: 99] [Article Influence: 7.9] [Reference Citation Analysis]
163 Kim SH, Choi D, Lim JH, Lee WJ, Jang HJ, Lim HK, Lee SJ, Cho JM, Kim SK, Kim GC. Optimal pulse sequence for ferumoxides-enhanced MR imaging used in the detection of hepatocellular carcinoma: a comparative study using seven pulse sequences. Korean J Radiol 2002;3:87-97. [PMID: 12087198 DOI: 10.3348/kjr.2002.3.2.87] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
164 Choi JY, Kim MJ, Kim JH, Kim SH, Ko HK, Lim JS, Oh YT, Chung JJ, Yoo HS, Lee JT, Kim KW. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging. Eur J Radiol 2006;60:84-90. [PMID: 16920315 DOI: 10.1016/j.ejrad.2006.06.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
165 Lewis KH, Chezmar JL. HEPATIC METASTASES. Magnetic Resonance Imaging Clinics of North America 1997;5:319-30. [DOI: 10.1016/s1064-9689(21)00198-7] [Cited by in Crossref: 11] [Article Influence: 0.4] [Reference Citation Analysis]
166 Kwak HS, Lee JM, Kim YK, Lee YH, Kim CS. Detection of hepatocellular carcinoma: comparison of ferumoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging. Eur Radiol 2005;15:140-7. [PMID: 15449000 DOI: 10.1007/s00330-004-2508-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
167 Stirrat CG, Alam SR, MacGillivray TJ, Gray CD, Forsythe R, Dweck MR, Payne JR, Prasad SK, Petrie MC, Gardner RS, Mirsadraee S, Henriksen PA, Newby DE, Semple SI. Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T. J Cardiovasc Magn Reson 2016;18:46. [PMID: 27465647 DOI: 10.1186/s12968-016-0261-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
168 Siegrist S, Cörek E, Detampel P, Sandström J, Wick P, Huwyler J. Preclinical hazard evaluation strategy for nanomedicines. Nanotoxicology 2019;13:73-99. [PMID: 30182784 DOI: 10.1080/17435390.2018.1505000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
169 Yousaf MZ, Yu J, Hou Y, Gao S. Magnetic nanoparticle-based cancer nanodiagnostics. Chinese Phys B 2013;22:058702. [DOI: 10.1088/1674-1056/22/5/058702] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
170 Schima W, Mukerjee A, Saini S. Contrast-enhanced MR imaging. Clinical Radiology 1996;51:235-44. [DOI: 10.1016/s0009-9260(96)80339-4] [Cited by in Crossref: 18] [Article Influence: 0.7] [Reference Citation Analysis]
171 Kim SK, Kim SH, Lee WJ, Kim H, Seo JW, Choi D, Lim HK, Lee SJ, Lim JH. Preoperative Detection of Hepatocellular Carcinoma: Ferumoxides-Enhanced Versus Mangafodipir Trisodium—Enhanced MR Imaging. American Journal of Roentgenology 2002;179:741-50. [DOI: 10.2214/ajr.179.3.1790741] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
172 Raman SS, Lu DS, Chen SC, Sayre J, Eilber F, Economou J. Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases. AJR Am J Roentgenol 2001;177:807-12. [PMID: 11566677 DOI: 10.2214/ajr.177.4.1770807] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
173 Smith JT, Ward J, Guthrie JA, Sheridan MB, Boyes S, Wilson D, Wyatt JI, Treanor D, Robinson PJ. Detection of colorectal metastases in patients being treated with chemotherapy utilising SPIO-MRI: a radiological–pathological study. Magnetic Resonance Imaging 2012;30:1446-53. [DOI: 10.1016/j.mri.2012.04.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
174 Poeckler–schoeniger C, Koepke J, Gueckel F, Sturm J, Georgi M. MRI with superparamagnetic iron oxide: efficacy in the detection and characterization of focal hepatic lesions. Magnetic Resonance Imaging 1999;17:383-92. [DOI: 10.1016/s0730-725x(98)00180-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
175 Ghaghada KB, Colen RR, Hawley CR, Patel N, Mukundan S. Liposomal Contrast Agents in Brain Tumor Imaging. Neuroimaging Clinics of North America 2010;20:367-78. [DOI: 10.1016/j.nic.2010.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
176 Braga HJ, Imam K, Bluemke DA. MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension. AJR Am J Roentgenol. 2001;177:111-114. [PMID: 11418408 DOI: 10.2214/ajr.177.1.1770111] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
177 Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R. Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A 2008;105:7387-92. [PMID: 18492802 DOI: 10.1073/pnas.0802878105] [Cited by in Crossref: 198] [Cited by in F6Publishing: 165] [Article Influence: 14.1] [Reference Citation Analysis]
178 Muldoon LL, Sàndor M, Pinkston KE, Neuwelt EA. Imaging, Distribution, and Toxicity of Superparamagnetic Iron Oxide Magnetic Resonance Nanoparticles in the Rat Brain and Intracerebral Tumor. Neurosurgery 2005;57:785-96. [DOI: 10.1227/01.neu.0000175731.25414.4c] [Cited by in Crossref: 118] [Article Influence: 6.9] [Reference Citation Analysis]
179 Oliva MR, Saini S. Liver cancer imaging: role of CT, MRI, US and PET. Cancer Imaging 2004;4 Spec No A:S42-6. [PMID: 18215974 DOI: 10.1102/1470-7330.2004.0011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
180 Murillo TP, Sandquist C, Jacobs PM, Nesbit G, Manninger S, Neuwelt EA. Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. Therapy 2005;2:871-82. [DOI: 10.2217/14750708.2.6.871] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
181 Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, Laniado M, Manfredi RM, Mathieu DG, Mueller D, Reimer P, Robinson PJ, Strotzer M, Taupitz M, Vogl TJ; European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275. [PMID: 14695400 DOI: 10.1148/radiol.2301020269] [Cited by in Crossref: 330] [Cited by in F6Publishing: 289] [Article Influence: 18.3] [Reference Citation Analysis]
182 Nakayama M, Yamashita Y, Mitsuzaki K, Yi T, Arakawa A, Katahira K, Nakayama Y, Takahashi M. Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging. J Magn Reson Imaging 2000;11:647-54. [DOI: 10.1002/1522-2586(200006)11:6<647::aid-jmri11>3.0.co;2-f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
183 Gomi T, Nagamoto M, Tsunoo M, Terada S, Terada H, Kohda E. Evaluation of the changes in signals from the spleen using ferucarbotran. Radiat Med 2007;25:135-8. [PMID: 17450339 DOI: 10.1007/s11604-006-0108-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
184 Kang BK, Lim JH, Kim SH, Choi D, Lim HK, Lee WJ, Lee SJ. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology. 2003;226:79-85. [PMID: 12511672 DOI: 10.1148/radiol.2261011827] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]